While flow cytometry shines by its flexibility, it requires a high level of expertise in antibody panel development, relies on experienced operators and is often challenged by inconsistent and unstable reagent quality. DURAClone dry antibody panels and stimulation mixes are a game-changer in conducting flow cytometry as they eliminate the burden of panel design, reduce reagent aging and at the same time remove antibody pipetting and stimulant handling from the resulting streamlined workflow. What has started with a small set of basic antibody panels descending from clinical studies such as The ONE Study (Sawitzki et al. Lancet. 2020), has grown to a broad range of 22 assays today, covering phenotypic and functional flow assays. If you want to accelerate your pace in clinical research (DURAClone IM),  make sure you catch those cell events you cannot afford to miss (DURAClone RE),  be sure about the response (DURAClone IF) and seize the potential (DURAClone SC), then join the DURAClone revolution in flow cytometry!

 

Learning Objectives: